Last quarter (Q ), Immage Biotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Immage Biotherapeutics's net income was $-44.09K. See Immage Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Aug 16	Aug 15	Sep 14	Aug 14	Sep 13
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Operating Expense	$ 1.83M	$ 216.48K	$ 53.87K	$ 18.55K	$ 18.30K	$ 12.01K
Operating Income	$ -1.83M	$ -216.48K	$ -53.87K	$ -18.55K	$ -18.30K	$ -12.01K
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	-	-	-	-	-	-
Pretax Income	$ -1.83M	$ -216.48K	$ -53.87K	$ -18.55K	$ -18.30K	$ -12.01K
Tax Provision	-	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -1.83M	$ -216.48K	$ -53.87K	$ -18.55K	$ -18.30K	$ -12.01K
Basic EPS	$ -0.01	$ >-0.01	$ >-0.01	$ 0.00	$ 0.00	$ 0.00
Diluted EPS	$ -0.01	$ >-0.01	$ >-0.01	$ 0.00	$ 0.00	$ 0.00
Basic Average Shares	$ 594.80M	$ 145.31M	$ 101.99M	$ 561.29M	$ 598.82M	$ 1.36B
Diluted Average Shares	$ 594.80M	$ 145.31M	$ 101.99M	$ 561.29M	$ 598.82M	$ 1.36B
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 1.83M	$ 216.48K	$ 53.87K	$ 18.55K	$ 18.30K	$ 12.01K
Net Income From Continuing And Discontinued Operation	$ -1.83M	$ -216.48K	$ -53.87K	$ -18.55K	$ -18.30K	$ -12.01K
Normalized Income	$ -1.83M	$ -216.48K	$ -53.87K	$ -18.55K	$ -18.30K	$ -12.01K
Interest Expense	-	-	-	-	-	-
EBIT	$ -1.83M	$ -216.48K	$ -53.87K	$ -18.55K	$ -18.30K	$ -12.01K
EBITDA	$ -1.82M	$ -207.95K	$ -53.10K	$ -18.55K	$ -18.30K	$ -12.01K

Currency in USD

Immage Biotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing